Notification
No new Notification messages
Zinka Logistics Solutions IPO is Open!
Apply for the Zinka Logistics Solutions IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Mankind Pharma Acquires Bharat Serums and Vaccines for ₹13,630 Crore

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Mankind Pharma acquires Bharat Serums and Vaccines for ₹13,630 crore, enhancing its leadership in women's health and fertility drugs. Mankind Pharma’s share price rose by 1.81% to ₹2143.90, with a market cap close to ₹86,000 crore.

Mankind Pharma News Today

Mankind Pharma's share price today is set to be in the spotlight following the announcement of its acquisition of Bharat Serums and Vaccines (BSV) from Advent International. This move aims to strengthen Mankind Pharma's portfolio in high-entry barrier products and secure its leadership in women's health.

Acquisition Details

Mankind Pharma has signed a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines from Advent International, a leading global private equity investor, for an enterprise value of ₹13,630 crore, subject to closing adjustments.

The acquisition aligns with Mankind Pharma's strategy to strengthen its position in the women's health and fertility drug market.

Strategic Significance

The acquisition of BSV represents a significant milestone for Mankind Pharma. It positions the company as a market leader in the Indian women's health and fertility segment while providing access to high-entry barrier products in critical care.

BSV's established R&D technology platforms and robust branded product portfolio in women's health, fertility, and critical care further enhance Mankind Pharma's capabilities.

Market Reaction

Following the acquisition announcement, Mankind Pharma share price rose by over 1.81%, settling at ₹2143.90 on Thursday. The company's market capitalization reached approximately ₹86,000 crore.

Mankind Pharma's stock has nearly doubled in value since its initial public offering (IPO) in May 2023, which raised ₹4,326.36 crore at an IPO price of ₹1,080 per share.

Future Outlook

Rajeev Juneja, Vice-chairman and Managing Director of Mankind Pharma, highlighted the substantial opportunities and growth potential in the women's health and fertility segment, driven by structural tailwinds globally.

The acquisition of BSV is expected to propel Mankind Pharma's market leadership and enhance its growth prospects in the high-potential segments.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text